

## ***SPECIAL STATUS APPLICATION***

Appl. No. 10/659,413

Amendment and Reply responsive to Final Office Action mailed April 12, 2005

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

#### **Listing of Claims:**

Claims 1-31 (canceled)

32. (currently amended) An antiseptic composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) ~~and a solvent~~ in solution, wherein the at least one EDTA salt comprises tetra-sodium EDTA ~~and is~~ at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, and wherein the antiseptic composition is packaged in a sterile, pyrogen-free form ~~safe and biocompatible, at least in modest volumes, in a patient's bloodstream.~~

Claim 33 (canceled)

34. (currently amended) A composition of ~~any~~ either of claims 32, 54, 55, or 56, comprising tri-sodium and tetra-sodium EDTA.

Claims 35-36 (canceled)

37. (currently amended) A composition of any of claims 32, ~~54, 55, or 56,~~ or 57, wherein the ~~solvent~~ solution comprises less than 10% (v/v) ethanol and water.

Claim 38 (canceled)

39. (currently amended) A composition of any of claims 32, ~~54, 55 or 56,~~ or 57, wherein the ~~solvent~~ solution comprises saline.

## ***SPECIAL STATUS APPLICATION***

Appl. No. 10/659,413

Amendment and Reply responsive to Final Office Action mailed April 12, 2005

Claim 40 (canceled)

41. (currently amended) A composition of any of claims 32, 55 or 57 formulated for topical application to surfaces and objects.

42. (currently amended) A composition of any of claims 32, ~~54, 55, or 56~~ or 57, comprising tri- and tetra-sodium EDTA salts in an aqueous ~~solvent~~ solution at a concentration of between 2.0% and 8.0% (w/v) EDTA salt(s).

Claim 43 (canceled)

44. (currently amended) A composition of ~~any of claims 32, 54, or 55, or 56,~~ in a sterile, pyrogen-free form.

45. (currently amended) A composition provided in a dry or partially hydrated formulation that, upon reconstitution with a ~~solvent~~ solution, forms an antiseptic composition of any of claims 32, ~~54, 55, or 56~~ or 57.

46. (currently amended) A composition of any of claims 32, ~~54, 55, or 56~~ or 57 ~~in a sterile condition~~ in a pre-filled syringe.

47. (currently amended) A composition of any of claims 32, ~~54, 55, or 56~~ or 57 ~~in a sterile condition~~ in a single-dosage vial.

Claims 48-54 (canceled)

55. (currently amended) An antiseptic composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) ~~and a solvent~~ in solution, wherein the at least one EDTA salt comprises tetra-sodium EDTA ~~and is~~ at a concentration of at least 2.0% (w/v) and less than 15%

## ***SPECIAL STATUS APPLICATION***

Appl. No. 10/659,413

Amendment and Reply responsive to Final Office Action mailed April 12, 2005

(w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, wherein the solution is water, and wherein the antiseptic composition has an osmolarity of from 240 – 500 mOsM/Kg.

56. (currently amended) A lock flush composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) ~~and a solvent~~ in solution, wherein the at least one EDTA salt comprises tetra-sodium EDTA ~~and is~~ at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the lock flush composition has a pH of at least 9.5, wherein the lock flush composition is packaged in a sterile, pyrogen-free form, and wherein the lock flush composition is ~~safe and~~ biocompatible for use in in-dwelling access catheters, urinary catheters, nasal tubes and throat tubes.

57. (new) An antiseptic composition comprising tri-sodium and tetra-sodium ethylene diamine tetraacetic acid (EDTA) in solution at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, and wherein the antiseptic composition is packaged in a sterile, pyrogen-free form.